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ABSTRACT
Invasive aspergillosis (IA) remains a major complication following allogeneic hematopoietic stem cell trans-
plant (HSCT). In contrast to conventional HSCT, few investigators have examined risk factors of IA associated
with nonmyeloablative (NMA) regimens characterized by outpatient administration, immunosuppression
rather than cytoreduction, and short duration of neutropenia posttransplant. We report our results on a cohort
of 125 patients treated homogenously who received a 6/6 matched sibling NMA HSCT designed to be
performed on an outpatient basis. Conditioning regimen included fludarabine (30 mg/m2  5 days) and
cyclophosphamide (300 mg/m2  5 days) followed by reinfusion of a minimum of 4  106 CD34 cells/kg.
Acute graft-versus-host disease (aGVHD) prophylaxis consisted of tacrolimus and mycophenolate mofetil
(MMF). Overall, 13 patients developed IA (5 proved, 6 probable, 2 possible) 44-791 days (median 229) after
NMA HSCT, with a risk of 7% at 1, 11% at 2, and 15% at 3 years. Patients who suffered from IA had poorer
overall survival (crude hazard ratio 2.3; 95% confidence interval [CI] 1.0-5.4; P  .045). Intestinal aGVHD or
chronic GVHD (cGVHD) was significantly associated with IA at 1 (27% versus 3%, P  .003), 2 (27% versus
8%, P  .01), and 3 years (37% versus 10%, P  .005). The use of daclizumab was also significantly associated
with IA at 3 years (47% versus 12%, P  .02). Age, sex, diagnosis, previous autologous transplant, duration of
neutropenia, occurrence of cytomegalovirus viremia, duration of steroids or MMF intake, aGVHD, cGVHD,
and cumulative number of days spent in hospital were not associated with IA. After multivariate analysis,
intestinal GVHD remained the only statistically significant risk factor for IA at 1 (P  .003), 2 (P  .01), and
3 years (P  .005). We conclude that in NMA HSCT, the risk of IA increases over time and is significantly
associated with intestinal GVHD. Because there is currently no surrogate in vitro markers of immunocom-
petence following NMA HSCT, this clinical finding is of particular importance to identify a population at
higher risk who should be targeted for antimold prophylaxis.
© 2007 American Society for Blood and Marrow Transplantation
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lNTRODUCTION
Invasive aspergillosis (IA) is a major complication
f allogeneic hematopoietic stem cell transplantation
HSCT), occurring in 10%-15% of patients with ap-
roximately a 50% mortality rate despite appropriate
ntifungal therapy [1]. This high case fatality ratio is
xplained by the inability to improve the immunosup- g
192ression status associated with the underlying hema-
ologic disease or therapy-associated complications.
he use of intensive cytoreductive conditioning regi-
ens, histoincompatibility, unrelated donors, T cell
epletion (TCD) prolonged neutropenia, cytomega-
ovirus (CMV) disease, acute and extensive chronic
raft-versus-host disease (aGVHD, cGVHD), as well
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Aspergillosis Associated with Intestinal GVHD 1193s care in a room without efﬁcient air ﬁltration have
een reported as independent risk factors for IA in
onventional allogeneic HSCT [2-6].
Over the last decade, there has been a signiﬁcant
hange in conditioning regimens used prior to alloge-
eic HSCT. Nonmyeloablative (NMA) preparations
ave become increasingly used to reduce immediate
osttransplant complications and broaden access to
lder patients and candidates with comorbidities who
ould not otherwise be eligible for conventional
SCT [7-12]. In contrast to conventional condition-
ng regimens using high-dose chemo- and/or radia-
ion therapy, NMA regimens use immunosuppressive
gents such as low-dose irradiation, ﬂudarabine, and
ntithymocyte globulin (ATG) resulting in signiﬁ-
antly less mucositis, shorter duration of cytopenias,
nd decreased transfusion requirements. Conse-
uently, several transplant teams are now performing
MA on an outpatient basis, a major change in par-
digm because allogeneic transplant recipients are no
onger conﬁned to a highly protective environment
ut sent back to their own community [13-15].
Despite the use of NMA conditioning regimens,
he promise of lower risks of aGVHD and cGVHD,
otentially because of a less intense cytokine storm,
as not always materialized, ranging from 30% to
0% and 50% to 70%, respectively [7,16-18]. Such
ariations reﬂect heterogeneity of both transplant re-
ipients (particularly age at transplant, a well-known
isk factor for GVHD) and GVHD prophylaxis regi-
ens. Consequently, most allogeneic NMA HSCT
ecipients need immunosuppressors for a prolonged
eriod of time after transplant and become at risk for
ife-threatening fungal infection such as IA.
To date, it remains unclear whether risk factors
or IA are the same in NMA and conventional alloge-
eic HSCT. In the present study, we describe the
ncidence, clinical characteristics, and outcomes of IA
n a large cohort of 125 patients who received NMA
SCT on an outpatient basis.
ATIENTS AND METHODS
ransplant Eligibility Criteria
NMA HSCT eligibility criteria included age 65
ears, a recognized indication for allogeneic transplant
ccording to our transplant program, and a 6/6 HLA-
ompatible sibling donor. Mismatched or unrelated
ransplant candidates were excluded from this study.
ligible patients were offered treatment on this pro-
ocol either because they were unﬁt to undergo stan-
ard myeloablative transplant or because of age 55
ears. Patients with newly diagnosed multiple my-
loma were also invited to participate in a sequential
herapy protocol (tandem) consisting of autologous
ransplantation followed by NMA transplant. Written
nformed consent was obtained from all patients. ionditioning Regimen and aGVHD Prophylaxis
Our reduced intensity conditioning (RIC) regi-
en was designed to be performed as an outpatient
rocedure at Hôpital Maisonneuve-Rosemont
HMR), a 725-bed tertiary care center afﬁliated to the
niversity of Montreal, Quebec, Canada. The condi-
ioning regimen consisted of ﬂudarabine 30 mg/m2
ntravenously (i.v.) and cyclophosphamide 300 mg/m2
.v. daily from day 8 to day 4, given from Monday
o Friday in our ambulatory care facility. Tacrolimus
as started at 3 mg twice a day orally on day 8 to
btain therapeutic levels (10-12 g/L) by day 0. Ther-
peutic levels were maintained until day50 and then
apered by day 100 (high-risk patients) or day 180
standard-risk patients) according to estimated risk of
elapse. Patients with chronic myelogenous leukemia
CML) in chronic phase, acute myelogenous leukemia
AML) in ﬁrst complete remission, acute lymphoblas-
ic leukemia (ALL) in ﬁrst complete remission, or
efractory anemia with or without ring sideroblasts
ere considered standard risk, whereas all other dis-
ases were classiﬁed as high risk. Donors received
ranulocyte-colony stimulating factor (G-CSF) 5
g/kg subcutaneously twice a day for 9 doses, and
ere collected by daily apheresis to reach a target of
4  106 CD34 cells/kg. Allogeneic stem cells were
nfused on day 0 after being stored at 4°C overnight,
nd no attempt was made to limit numbers of CD34
ells infused. Mycophenolate mofetil (MMF), used
nstead of methotrexate to avoid mucositis, was initi-
ted at 1000 mg twice a day orally 24 hours after the
ast infusion of stem cells and discontinued without
apering on day 50. MMF was not weight adjusted
nd levels were not measured. aGVHD and cGVHD
ere graded according to clinical presentation with
ppropriate biopsies using previously reported cri-
eria [19-21].
All recipients were followed in the outpatient
linic by the same medical and nursing staff thrice
eekly until neutropenia resolved and every 1-2 weeks
hereafter. Red blood cells (RBC) or platelet transfu-
ions were given when hemoglobin was 85 g/L or
latelet count 15  109/L. Chimerism studies were
erformed using short variable tandem repeats by
olymerase chain reaction (PCR) assay (GenePrint
TR Systems, Promega, Madison, WI) in both lym-
hocytes and neutrophils every 2 weeks for the ﬁrst 8
eeks, then monthly for 2 months, and every 3
onths thereafter.
ntimicrobial Prophylaxis
Trimethoprim/sulfamethoxazole (TMP/SMX) 1
ouble strength tablet twice a day was given on week-
nd days for Pneumocystis jirovecii prophylaxis starting
ay 3 until 1 month after discontinuation of all
mmunosuppression. Patients seropositive for herpes
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A.-C. Labbe´ et al.1194implex received acyclovir 200 mg three times a day
rally from day 8 until day 21. CMV seropositive
ecipients or recipients transplanted from a CMV-
eropositive donor were followed using a preemptive
pproach of weekly quantitative PCR (Cobas Ampli-
or CMV Monitor, Roche Diagnostics, Branchburg,
J) from day 14 until day 100 [22]. Upon detec-
ion of CMV viremia, patients were promptly treated
ith intravenous ganciclovir 5 mg/kg twice a day for a
inimum of 4 weeks and until weekly negative CMV
CR were obtained over 2 weeks. No patient had
reviously had IA and no antifungal prophylaxis was
dministered. G-CSF was only used in neutropenic
atients with fever or documented infection and
iscontinued as soon as neutrophils reached 1.5 
09/L. Patients developing aGVHD and cGVHD
eceived TMP/SMX twice a day until immunosup-
ression was completely discontinued. Immunoglobu-
ins (i.v.) (0.5 mg/kg every 28 days) were not routinely
sed after transplant but given to patients with bron-
hiolitis obliterans or in presence of hypogamma-
lobulinemia and recurrent respiratory infections.
reatment of GVHD
Brieﬂy, patients with grade I aGVHD were
reated with topical steroids. All patients with a diag-
osis of grade II-IV aGVHD received methylpred-
isolone 1 mg/kg i.v. twice a day for 8 doses; respond-
rs were then treated with methylprednisolone 0.9
g/kg i.v. twice a day for 8 doses, then 0.8 mg/kg i.v.
wice a day for 8 additional doses, then switched to
rednisone 1.4 mg/kg daily for 1 week, after which
rednisone was subsequently tapered to 0.6 mg/kg
ver 3 weeks (weeks 1-4). Prednisone was then de-
reased to 0.6 mg/kg every other day over 3 weeks
weeks 5-7) and tapered completely over 3 more weeks
weeks 8-10). Tacrolimus blood levels were main-
ained between 10 and 15 g/L for 4 weeks, then
apered progressively until day 180. Patients not
esponding or progressing after 8 doses of methyl-
rednisolone and those with grades III-IV at presen-
ation received MMF 15 mg/kg i.v. twice a day,
hereas patients unresponsive/refractory to steroids
ere given daclizumab 1 mg/kg i.v.  5 doses [23].
atients improving following MMF or daclizumab
eceived prednisone for a total of 8 weeks; MMF and
acrolimus were both given for 4 months, after which
MF was tapered over 4 weeks. Tacrolimus was sub-
equently stopped 4 weeks later. Progressing/relaps-
ng patients at taper were retreated with i.v. methyl-
rednisolone, tacrolimus, MMF, and daclizumab as
reviously reported [23,24].
Patients with extensive cGVHD were all treated
ith systemic therapy. De novo and quiescent
GVHD were treated with prednisone 1 mg/kg daily
or 6-8 weeks; responsive patients were then switched ao prednisone 1 mg/kg every other day and treated for
minimum of 4 months, followed by a taper of 10
g/kg/week until complete discontinuation.
Unresponsive/relapsing patients received cyclo-
porine A (CSA) 10 mg/kg/day (or tacrolimus 0.1
g/kg/day) every other day in addition to prednisone
or a minimum of 6 months; calcineurin inhibitors
ere then tapered progressively over 4-6 weeks 1
onth after discontinuation of prednisone. Pro-
ressive cGVHD was treated with both CSA 10 mg/
g/day and prednisone 1 mg/kg/day for 4 weeks; pa-
ients improving were then switched to alternate
herapy for 9 months, after which prednisone was ﬁrst
apered over 10 weeks, followed by CSA over 10
eeks. In addition, unresponsive/progressing pa-
ients were treated with MMF 15 mg/kg by mouth
wice a day. Daclizumab 1 mg/kg  5 doses was used
n patients with cGVHD unresponsive to the triple
ombination of prednisone, a calcineurin inhibitor,
nd MMF.
iagnosis of Invasive Aspergillosis
IA was deﬁned according to the European Orga-
ization for Research and Treatment of Cancer/My-
oses Study Group (EORTC/MSG) criteria [25].
roven disease required histopathologic or microbio-
ogic documentation of disease in tissues, whereas
robable infection was deﬁned by identiﬁcation of
ungus from culture of bronchoalveolar lavage (BAL)
uid in a patient with 1 major (typical new inﬁltrates
n CT imaging) or 2 minor clinical criteria (symp-
oms, signs on physical examination, or nonspeciﬁc
nﬁltrate on CT imaging). IA was considered possible
f Aspergillus sp. was isolated from BAL in a patient
ith only 1 minor clinical criterion. The day on which
he ﬁrst positive diagnostic test was performed was
onsidered the day of diagnosis. Because the galacto-
annan assay was not routinely nor prospectively used
n our institution during the study period, this data
as not included in our analysis.
tatistical Analysis
The risk of developing IA over time was calculated
sing Kaplan-Meier plots, in which day 0 was the day
f NMA HSCT and the end point was the day of
iagnosis of IA, with censoring at the date of last
ollow-up or death. Risk factors associated with IA
ere identiﬁed in univariate and multivariate Cox re-
ression models. Results are expressed as crude
CHR) and adjusted hazard ratios (AHR) with their
5% conﬁdence intervals (CI). Models were built up
equentially, starting with the variable most strongly
ssociated with the outcome and continuing until no
ther variable reached signiﬁcance or altered the haz-
rd ratios of variables already in the model.
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Aspergillosis Associated with Intestinal GVHD 1195ESULTS
Between July 2000 and June 2006, 125 consecutive
atients underwent outpatient NMA HSCT at HMR.
edian follow-up period of our cohort is 2 years, and
anges from 70 days to 5.7 years. Patients’ character-
stics are shown in Table 1. Median age at transplan-
ation was 53 years (range: 20-65) and the most com-
on indication was multiple myeloma (45% of all
atients). Previous autologous HSCT was done in 88
70%) patients, either as part of an upfront tandem
rocedure (n  36) or as dictated by the patients’
edical condition (n  52). Engraftment occurred in
ll patients but 4 (2 with CML and 2 with chronic
yelomonocytic leukemia). Severe neutropenia
0.1  109/L) following transplant occurred in only
9 (15%) patients and was of short duration (median 3
ays, range: 1-4).
Overall, CMV viremia was detected in 44 (35%)
atients, a median of 7 weeks post-NMA HSCT. Of
able 1. Characteristics of 125 Patients Who Underwent Outpatient
MA Allogeneic HSCT
Number of Patients
N  125 (%)
ge (years)
20-44 11 (9)
45-49 24 (19)
50-54 32 (26)
55-59 28 (22)
>60 30 (24)
ex (M/F) 70 (56)/55 (44)
ndication for NMA HSCT
Multiple myeloma 56 (45)
Non-Hodgkin lymphoma 34 (27)
Other hematologic malignancies 35 (28)
revious autologous transplant 88 (70)
evere neutropenia following NMA
HSCT* 19 (15)
ytomegalovirus viremia† 44 (35)
rades II-IV aGVHD 8 (6)
GVHD 95 (76)
ntestinal GVHD‡ 21 (17)
uration of MMF intake (days)
30-59 days 66 (53)
>60 days 59 (47)
se of steroids 101 (81)
0 day 24 (19)
1-59 days 11 (9)
>60 days 90 (72)
se of daclizumab 8 (6)
eed for hospital admission† 83 (66)
MA indicates nonmyeloablative; HSCT, hematopoietic stem cell
transplant; GVHD, graft-versus-host disease; aGVHD, acute
graft-versus-host disease; cGVHD, chronic graft-versus-host
disease.
Severe neutropenia deﬁned as neutrophils 0.1  109/L within 30
days of conditioning regimen.
At any time following NMA HSCT.
Intestinal GVHD was deﬁned as aGVHD or cGVHD with intes-
tinal involvement.hese, 41 had viremia within 6 months of NMA iSCT. aGVHD developed in only 14 patients (11%):
had grade I, 6 grade II, and 2 grade III aGVHD. In
harp contrast, extensive cGVHD was identiﬁed in 95
atients (76%). Only 5 patients suffered from both
GVHD and cGVHD. Intestinal involvement (by ei-
her aGVHD or cGVHD) occurred in 21 patients
17%). In 20 patients, intestinal GVHD occurred
ithin 6 months of NMA HSCT (range: 36-154 days;
edian 128), and in 1 patient 23 months posttrans-
lant. MMF administration ranged from 36 to 1704
ays, with 47% of patients receiving at least 60 days.
teroids were required for most (81%) patients for a
ean duration of 15 months (median 10 months).
aclizumab was administered in 8 patients (6%), all
ith severe intestinal GVHD.
Although our NMA protocol was designed to be
erformed on an outpatient basis, hospitalization at
ny given time between stem cell infusion and the last
ollow-up visit was required for 83 (66%) patients.
he most common causes of ﬁrst hospitalization fol-
owing transplant included complications related to
GVHD or cGVHD (n  16; 20%), pneumonia, or
ther bacterial infections (n  15; 19%), varicella-
oster infections (n 6; 7%), febrile neutropenia (n
; 7%), relapse of initial hematologic malignancy (n
; 7%), CMV disease (n 3; 4%), and IA (n 3; 4%).
he cumulative number of days spent in the hospital
t any time following NMA HSCT ranged from 2 to
58 (median 18 days).
Overall, 13 patients developed IA, with an inci-
ence of 70 of 1000 persons-year at 1 year, 110 of
000 persons-year at 2 years, and 150 of 1000 persons-
ear at 3 years. Of our 13 patients with IA, 5 were
lassiﬁed as proven, 6 as probable, and 2 as possible.
A was diagnosed between 44 and 791 (median 229)
ays after NMA HSCT (Table 2). Six patients with
ntestinal GVHD experienced IA, 40-102 (median 68)
ays after diagnosis of intestinal GVHD. In 4 patients,
A occurred while GI GVHD was active and poorly
ontrolled. Two outpatients were diagnosed (2 and 3
onths) after GI GVHD clinical manifestations had
esolved but while still taking heavy immunosuppres-
ion. No case of intestinal IA was observed. The di-
gnosis was clinically unsuspected and established at
utopsy in 1 patient; all other patients received appro-
riate antifungal therapy for a median of 70 days
range: 5-194). Seven patients died: 6 while on appro-
riate antifungal therapy for 5 to 189 days, and the
ther 6 months after completing antifungal therapy.
Survival at 1, 2, and 3 years following NMA
SCT in all 125 patients was 86%, 79%, and 72%,
espectively. As shown in Figure 1, patients who suf-
ered from IA had poorer survival (overall CHR 2.3;
5% CI 1.0-5.4; P .045): 77% versus 88% at 1 year,
9% versus 80% at 2 years, and 43% versus 77% at 3
ears. Death was considered directly attributable to IA
n 2 patients: 1 died before the diagnosis of IA was
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A.-C. Labbe´ et al.1196stablished, whereas the other expired 6 days later. IA
as a contributing cause in 4 additional patients who
ied from the following (days after diagnosis of IA):
eptic shock and acute respiratory distress syndrome
day4), CMV pneumonia (day7), pulmonary plas-
ocytoma (day 15), and severe refractory cGVHD
ith multiple organ failure (day 105). Finally, 1
atient died from Clostridium difﬁcile colitis and pul-
onary mucormycosis 6 months after completing
nti-Aspergillus therapy.
able 2. Cases of Invasive Aspergillosis following Outpatient NMA
llogeneic HSCT in 125 Patients with Hematologic Malignancy
Species
Day after
NMA HSCT
Culture or
Histopathologic
Positive Specimen
roved
1 Aspergillus sp. 190 Autopsy
2 A. fumigatus 229 Autopsy*
3 A. fumigatus 239 Autopsy*
4 A. fumigatus 497 Autopsy*
5 A. fumigatus 793 Transbronchial biopsy
robable
6 Aspergillus sp. 44 Sputum
7 A. fumigatus 154 BAL  sputum
8 A. fumigatus 212 BAL
9 A. fumigatus 545 Sputum
10 A. glaucus 723 BAL
11 A. fumigatus 763 Sputum
ossible
12 A. fumigatus 169 Sputum
13 A. versicolor 188 BAL
indicates Aspergillus; NMA, nonmyeloablative; HSCT, hemato-
poietic stem cell transplant; BAL, bronchoalveolar lavage.
Clinical diagnosis was made before death on bronchoalveolar la-
vage (positive cultures).
igure 1. Kaplan-Meier probability of survival following NMA allo
log-rank test P  .045). NMA, nonmyeloablative; HSCT, hematopoieticWe then sought to identify potential risk factors
or IA following NMA HSCT and results of univari-
te analysis are shown in Table 3. Among the 14
atients who presented with aGVHD, 1 did so after
eveloping IA. IA following aGVHD occurred in 1 of
patients with grade I and in 2 of 6 patients with
rade II GVHD. Although the 1-year risk of IA was
igniﬁcantly higher among patients who developed
rades I-IV aGVHD (20% versus 6%, P .02), it was
o longer signiﬁcant when restricting to grades II-IV.
urprisingly, cGVHD was not associated with IA in
ur cohort of patients.
Among patients developing GVHD, we hypothe-
ized that more profound immunosuppression would
urther increase the risk of IA. Because intestinal
VHD is usually associated with prolonged hospital-
zations and immunosuppression, we elected to study
his subset of patients. We indeed found that intestinal
VHD, whether aGVHD (n  5) or cGVHD (n 
6), was signiﬁcantly associated with IA at 1 (27%
ersus 3%; CHR 8.9; 95%CI 2.1-37.4; P  .003), 2
27% versus 8%; CHR 4.6; 95%CI 1.4-15.1; P .01),
nd 3 (37% versus 10%; CHR 4.7; 95%CI 1.6-14.0;
 .005) years. Of note, 1 patient developed acute
ntestinal GVHD after diagnosis of IA and was there-
ore considered as not having developed intestinal
VHD for this analysis. Although the incidence of IA
as more frequent in patients taking steroids during
he study period (8% versus 3% at 1 year, 12% versus
% at 2 years, 16% versus 4% at 3 years), this obser-
ation did not reach statistical signiﬁcance. Among
00 patients taking steroids, 12 eventually developed
A; the risk was signiﬁcantly higher among those who
eceived 1-59 days of steroids at 2 (CHR 9.2; 95%CI
.0-83.4; P  .05) and 3 years post-NMA HSCT
HSCT in patients who did or did not develop invasive aspergillosisgeneic
stem cell transplant.
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Aspergillosis Associated with Intestinal GVHD 1197CHR 11.4; 95%CI 1.2-104.6; P  .03). Daclizumab
as given to 8 patients, but 3 of them developed IA. At
year posttransplant, patients who had received da-
lizumab were 5 times more at risk of developing IA
30% versus 6%; CHR 5.0; 95%CI 1.0-24.7; P 
able 3. Risk Factors for Invasive Aspergillosis among 125 Patients W
Patients with
IA/Total 1 Year
ohort overall 13/125 7
ge at time of HSCT
<55 years 8/67 9
>55 years 5/58 5
ex
Female 7/55 8
Male 6/70 7
MA HSCT indication
MM 8/56 10
NHL 4/34 9
Other 1/35 0
revious autologous HSCT
No 2/37 0
Yes 11/88 10
uration of neutropenia†
0-9 days 5/59 4
>10 days 8/66 11
MV viremia
No 7/81 5
Yes 6/44 14
GVHD (grades)‡
0-I 11/117 7
II-IV 2/8 14
GVHD (N  122)§
No 1/28 4
Yes 11/94 7
ntestinal GVHD‡
No 7/105 3
Yes 6/20 27¶
uration of MMF intake
30-59 days 5/66 10
>60 days 8/59 5
uration of steroid intake
0 1/25 3
1-59 days 4/13 30
>60 days 8/87 5
aclizumab
No 10/117 6
Yes 3/8 30#
umulative hospitalization—
days post-HSCT (hazard
ratio for each additional
day; 95% CI)
NA 1.007
(0.995-1.019) (0
A indicates invasive aspergillosis; HSCT, hematopoietic stem cell t
GVHD, graft-versus-host disease; aGVHD, acute graft-versus-
alovirus; MMF, mycophenolate mofetil; NA, not applicable.
Adjusted for presence of intestinal GVHD.
Neutropenia was deﬁned as neutrophils 0.5  109/L following
One patient developed acute intestinal GVHD after diagnosis of
GVHD for these analysis.
For cGVHD analysis, 3 cases were excluded because of death (n
Intestinal GVHD was deﬁned as aGVHD or cGVHD with intest
P  .01.
P  .05.049). At 3 years, having received daclizumab was even dore signiﬁcantly associated with the risk of IA (47%
ersus 12%; CHR 4.4; 95%CI 1.2-16.1; P .02). Age,
ex, underlying hematologic diagnosis, previous autol-
gous transplantation, duration of neutropenia fol-
owing NMA HSCT, occurrence of CMV viremia,
erwent Outpatient NMA Allogeneic HSCT
f IA (%) Crude Hazard
Ratio (95% CI)
Adjusted Hazard
Ratio (95% CI)*rs 3 Years
15
15 1.0 1.0
15 0.8 (0.3-2.4) 0.8 (0.2-2.3)
17 1.0 1.0
13 0.7 (0.2-2.0) 0.6 (0.2-1.9)
18 1.0 1.0
18 0.8 (0.2-2.6) 0.9 (0.3-3.1)
7 0.3 (0.03-2.2) 0.4 (0.04-3.7)
13 1.0 1.0
16 2.1 (0.5-9.5) 1.5 (0.3-7.2)
16 1.0 1.0
16 1.5 (0.5-4.6) 1.6 (0.5-4.8)
11 1.0 1.0
25 2.0 (0.7-6.0) 1.7 (0.6-5.1)
13 1.0 1.0
43 3.5 (0.8-15.8) 2.7 (0.7-9.9)
5 1.0 1.0
16 1.9 (0.3-15.1) 1.2 (0.2-10.2)
10 1.0 1.0
37¶ 4.7 (1.6-14.0)¶ 4.7 (1.6-14.0)¶
10 1.0 1.0
18 1.3 (0.4-3.9) 1.1 (0.3-3.3)
4 1.0 1.0
69# 10.2 (1.1-93.3)# 6.4 (0.6-62.7)
13 1.2 (0.1-9.3) 0.7 (0.08-6.1)
12 1.0 1.0
47# 4.4 (1.2-16.1)# 1.4 (0.3-7.1)
015)
1.004
(0.994-1.015)
1.004
(0.994-1.014)
1.002
(0.990-1.015)
ntation; MM, multiple myeloma; NHL, Non-Hodgkin lymphoma;
ease; cGVHD, chronic graft-versus-host disease; CMV, cytomeg-
ransplant.
was therefore considered as not having developed acute intestinal
development of IA (n  1) before day 100.
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A.-C. Labbe´ et al.1198ays spent in the hospital were not associated with IA
n univariate analyses.
Following multivariate analysis, intestinal GVHD
emained the only statistically signiﬁcant risk factor
or IA at 1, 2, and 3 years as well as for the entire
ollow-up period. All patients who received dacli-
umab had intestinal GVHD. Among patients who
id not receive daclizumab, intestinal GVHD re-
ained signiﬁcantly associated with IA (27% versus
0%; CHR 4.0; 95%CI 1.0-15.4; P  .046).
ISCUSSION
We report a risk of IA of 7% at 1 year, 11% at 2
ears, and 15% at 3 years in a large, homogenously
reated cohort of 125 HSCT recipients. Our cohort is
he largest reported thus far that speciﬁcally sought to
dentify both incidence and risk factors for IA among
ecipients of a 6/6 matched sibling NMA transplanta-
ion [26-29]. It is characterized by short duration of
eutropenia, absence of mucositis, and a very low risk
11%) of grade I-IV aGVHD, which allows transplant
o be conducted on an outpatient basis. Of note, a ma-
ority of patients (76%) experienced extensive cGVHD
equiring immunosuppression; 66% were eventually
ospitalized for a median of 18 days, primarily from
VHD-related conditions.
Increasing risk of IA over time in NMA transplant
ecipients has not been reported before. Previously
tudied NMA cohorts have either not stated a cumu-
ative risk [29] or published risks at 1 year only [26-
8]. Increasing risk over time most likely reﬂects on-
oing T cell function impairment from GVHD
nd/or immunosuppressive medication [5,6]. This
mphasizes the need for longer follow-up in patients
ho have received NMA transplantation to precisely
etermine those at risk of IA and the continuity in that
isk. Our 7% 1-year risk is lower than the 15% and
1% reported by the Seattle team in 2 cohorts of
MA transplant recipients of 56 (52 HLA-matched
elated donors; 4 HLA-matched unrelated donors)
nd 163 (108 HLA-matched related donors; 55 HLA-
atched unrelated donors) patients, respectively
26,27]. In contrast, it is higher than what has been
bserved by the Spanish Transplant Group (4%) in 71
ibling matched recipients [28]. The reasons for such
ariations remain unclear. Nevertheless, our observa-
ion of an increasing risk of IA over time indicates that
urther studies are needed to better deﬁne patients
ho could beneﬁt from systematic surrogate marker
urveillance and preemptive antifungal therapy. Oral
ntifungal therapy will be particularly challenging in
atients with intestinal GVHD owing to poor oral
olerance and potentially erratic drug absorption.
learly, future preemptive studies will need to addresshese issues. pOur most signiﬁcant ﬁnding is an association be-
ween IA and intestinal GVHD at 1, 2, and 3 years
osttransplant, which has not been reported before.
ollowing multivariate analysis, we found that intes-
inal GVHD was the only signiﬁcant risk factor for IA,
ith a risk 9-fold higher at 1 year and 5-fold higher at
and 3 years among patients with this complication.
ntestinal GVHD is a morbid complication of alloge-
eic HSCT that may occur early (as part of aGVHD)
r later (after day 100, as part of multisystemic
nvolvement of cGVHD) [30,31]. When compared to
onventional allogeneic HSCT, NMA HSCT is asso-
iated with a lower incidence of aGVHD but a similar
ate of cGVHD, as well as a late onset and more
evere gut morbidity occurring 6 to 12 months after
ransplant [32]. The change in presentation of GVHD
ollowing NMA transplant underlines the need to re-
isit the risk factors in this population [33].
The association between IA and intestinal GVHD
n our cohort of NMA recipients most likely reﬂects
he heavy immunosuppression encountered in these
atients. Patients with intestinal GVHD usually re-
uire aggressive treatment including hospitalization,
arenteral nutrition, and a combination of immuno-
uppressors for adequate control of disease. Intestinal
VHD manifestations usually resolve gradually,
hich in turn, results in prolonged hospitalization and
equires the use of several immunosuppressive drugs.
ur reported association between IA and the admin-
stration of daclizumab in steroid refractory intestinal
VHD patients is in keeping with this hypothesis
23,34-36]. Although survival rates of patients with IA
n our cohort are comparable to those observed after
onventional [2] or other NMA allogeneic transplant
eries [26], these characteristics are important to rec-
gnize because patients bearing them should be can-
idates for antimold prophylaxis [37]. Additionally,
linical criteria identifying patients at higher risk of
nfection may be particularly useful considering the
ack of surrogate in vitro markers of immunocompe-
ence. As a corollary, our observation of a higher risk
f IA in patients with intestinal GVHD emphasizes
hat not all patients with cGVHD have the same
egree of T cell deﬁciency, and that subsets of patients
hould be analyzed separately in the future. Further
tudies are also needed to decipher the mechanisms of
mmune deﬁciency associated with intestinal GVHD
nd clarify whether intestinal involvement aggravates
mmune deﬁciency or this condition requires more
mmunosuppression.
In contrast to conventional allogeneic HSCT, IA
as not associated with duration of neutropenia or
MV viremia in our cohort [2]. Infusion of blood
tem cells and the lack of methotrexate (MTX) for
VHD prophylaxis contributed to an extremely short
uration of neutropenia (median: 3 days) which was
resent in only a minority (15%) of patients, possibly
d
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Aspergillosis Associated with Intestinal GVHD 1199ecreasing the risk of IA immediately post transplant.
MV viremia was also managed with a preemptive
herapy approach using short course ganciclovir
voiding neutropenia. Similar to studies of risk factors
or IA in conventional HSCT, IA was not associated
ith age, sex, initial diagnosis, previous transplant,
nd use of MMF [26]. MMF is usually given in com-
ination with calcineurin inhibitors for prevention of
GVHD and with other immunosuppressors (steroids,
aclizumab) for treatment of cGVHD, making difﬁ-
ult the deﬁnition of its particular contribution to the
ccurrence of IA [27]. Finally, despite the fact that our
ohort of NMA sibling transplants is the largest re-
orted thus far, it remains limited by the few cases of
A observed. Given these limitations in power, it is
ossible that having intestinal GVHD ultimately rep-
esented a composite variable of the several modes of
mmunosuppression used for its control. A larger mul-
icentric study or meta-analysis might allow the iden-
iﬁcation of speciﬁc components of immunosuppres-
ion driving the risk of IA.
In conclusion, despite an apparent overall low risk
f IA in our population of NMA HSCT recipients, we
eport a high 1-year risk of IA of 27% in the subgroup
f patients who developed intestinal GVHD. These
atients most likely have profound T cell dysfunction
esulting from intensive immunosuppressive therapy
nd GVHD; they should be considered for close mon-
toring with surrogate markers of invasive mold infec-
ions as well as for antimold prophylaxis.
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